An interventional study of Bergen 4-Day Treatment (B4DT) and Gold standard cognitive behavioral therapy (gold standard CBT) in Obsessive-Compulsive Disorder, sponsored by Karolinska Institutet. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-07.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet — 3 open to participants now, 3 under way, none of them phase 3. Obsessive-Compulsive Disorder · Karolinska Institutet.
Among the 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 13 with no phase, and was the 15th registered.
637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.
Browse Obsessive-Compulsive Disorder studies →3 of the 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:
Karolinska Institutet · Sites in Sweden
Ages 18+
Karolinska Institutet · Sites in Sweden
Ages 7–17
By country, each count listing its studies:
Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 120 is above the median of 45 across 522 interventional studies indexed under Obsessive-Compulsive Disorder.
Median enrollment 83 across the 15 interventional studies, 125 across the 2 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
1 of the studies in Obsessive-Compulsive Disorder by Karolinska Institutet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206212Karolinska InstitutetA Lifestyle Intervention to Reduce Cardiometabolic Risk Factors in Individuals With Obsessive-compulsive Disorder | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare a novel, condensed version of cognitive behavioral therapy (Bergen 4-Day Treatment, B4DT) to the gold standard psychological treatment (gold-standard CBT) for obsessive compulsive disorder (OCD).
The main question it aims to answer is:
Adult patients with obsessive compulsive disorder will be randomly assigned to receive either gold standard CBT one to two times per week for 14 weeks, or 4 days of B4DT during one week.
Obsessive-compulsive disorder is a persistent and disabling psychiatric disorder. Individual cognitive behavioral therapy (CBT) with exposure and response prevention (ERP) is an effective treatment for OCD and is recommended as a first-line intervention. However, patients need to remain in treatment for several months and even after that, around 50% remain symptomatic despite this lengthy treatment. In response to this, a novel, condensed version of CBT, B4DT, has been developed. B4DT has shown promising results in several uncontrolled trials and one randomized controlled trial with inactive control, however it has yet to be directly compared to gold-standard individual CBT.
This single blind, randomized controlled trial with 120 patients (60 per arm) will compare B4DT to gold standard CBT. The primary outcome is the blind-rater administered Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). The investigators hypothesize that B4DT will be non-inferior to gold standard CBT 14 weeks after treatment start. The non-inferiority margin is set at 4 points on the Y-BOCS.
Secondary outcomes are cost effectiveness, speed of response, response and remission rates, dropout rate, and negative effects. The investigators hypothesise that participants that receive B4DT will improve faster than patients that receive standard CTB, but for the rest of the secondary outcomes, the investigators have no directed hypotheses.
A more detailed preregistration, and all analysis scripts, are available at Open Science Framework (https://osf.io/w5bfp/).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this arm will receive an intensive treatment delivered mostly in group format. The group sizes will be 3-6 participants with a 1:1 patient to therapist ratio. In the week before the intensive part of the treatment, participants will have two scheduled phone/video calls with a therapist. Day 1 (half-day) of the intensive treatment includes psychoeducation and deciding on exposure tasks. Days 2 and 3 (whole days) focus on individually tailored and therapist-assisted ERP in as many most relevant settings as possible. In the evenings, patients are encouraged to continue with self-guided ERP and may receive therapist support via text messages or phone calls on demand. On day 3, patients can invite relatives to a psychoeducation session. Day 4 (half-day) of the intensive treatment focuses on treatment summary and relapse prevention, as well as planning self-guided ERP for the upcoming 3 weeks. After 16 weeks, participants have individual follow-up sessions without ERP.
Behavioral: Bergen 4-Day Treatment (B4DT)
Patients will receive 16 sessions of individual CBT for OCD with an emphasis on ERP, delivered over a time period of 14 weeks according to a validated protocol. Sessions will be held twice weekly at a specialist clinic during the first 2 weeks and once a week for the remaining 12 weeks. Sessions 1-2 contain psychoeducation about OCD and CBT, goal setting, and planning of ERP exercises. Sessions 3-14 include therapist-guided ERP (at the clinic, in the patients' homes or elsewhere as needed) with planned self-practice ERP between sessions. Sessions 15-16 contain a summary of the treatment and lessons learned, as well as relapse prevention and planning of continued self-practice ERP.
Behavioral: Gold standard cognitive behavioral therapy (gold standard CBT)
Novel CBT treatment
Gold standard CBT treatment
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), clinician-administered
Clinician administered scale that measures the severity of obsessions and compulsions. Ten questions, with scores ranging from 0 to 4 (most severe), address time, interference, distress, resistance and control over obsessions and compulsions (total score range from 0 to 40).
Time frame: Change from baseline to 14 weeks after treatment start. Additional measures at week 4 and 7, and at the 7- and 16-month follow-up
Clinical Global Impression - Severity (CGI-S)
Used to assess rates of response and remission. The Clinical Global Impression - Severity (CGI-S) and Clinical Global Impression - Improvement (CGI-I) Scales will be used to assess overall clinical severity and consequent treatment response (scores of "very much improved" (1) or "much improved" (2) will define treatment response according to previous trials in tic disorders.
Time frame: 14 weeks after treatment start. Additional measures at week 4 and 7, and at the 7- and 16-month follow-up
Clinical Global Impression - Improvement (CGI-I)
Used to assess rates of response and remission. The Clinical Global Impression - Severity (CGI-S) and Clinical Global Impression - Improvement (CGI-I) Scales will be used to assess overall clinical severity and consequent treatment response (scores of "very much improved" (1) or "much improved" (2) will define treatment response according to previous trials in tic disorders.
Time frame: 14 weeks after treatment start. Additional measures at week 4 and 7, and at the 7- and 16-month follow-up
Dropout rate in both arms
A dropout will be defined as a patient in the B4DT arm that participates in less than 1.5 full days at the clinic, or a patient in the gold standard CBT arm that participates in less than 8 CBT sessions.
Time frame: Gold standard CBT: week 15. B4DT: week 3.
Treatment Inventory of Costs in Psychiatric Patients (TIC-P)
Self-rated questionnaire on healthcare utilization and productivity losses in patients with a psychiatric disorder. The TIC-P questionnaire measures costs in two dimensions: use of health resources and loss of productivity. Lower cost is better.
Time frame: Pre-treatment, at week 15, and at the 7- and 16-month follow-ups
Negative Effects Questionnaire (NEQ)
Self-rated questionnaire on negative effects. It contains 32 items that are scored on a five point Likert-scale (0-4) and differentiates between negative effects that are attributed to treatment and those possibly caused by other circumstances. The total score of the NEQ ranges from 0 to 80 points, a higher score reflects more negative effects.
Time frame: 14 weeks after treatment start. Additional measures at the 7- and 16-month follow-ups
Assessing Quality of Life 6 Dimensions (AQoL-6D)
Used to assess cost-effectiveness. 20 questions that assess different aspects of quality of life. The AQoL provides a utility score that ranges from 1.00 (full health) to 0.00 (death-equivalent health states) to -0.04 (health states worse than death).
Time frame: Change from baseline to 14 weeks after treatment start. Additional measures at the 7- and 16-month follow-ups
Patient Exposure/Response Prevention Adherence Scale (PEAS)
Measures the patient's between-session adherence to the therapist's exposure and response prevention instructions. The scale has three subscales: exposure assignments attempted, the quality of exposure assignments attempted, and the percentage of rituals resisted between session. Each subscale ranges from 0 to 100%, high scores represent better adherence.
Time frame: Gold standard CBT: week 4, 7, and 15. B4DT: week 3.
Yale-Brown Obsessive Compulsive Scale-Self-Rated (Y-BOCS-SR)
Self rated version of the primary outcome that measures severity of obsessions and compulsions. It consists of 10 items rated on a 5-point Likert scale (0 to 4) with higher scores denoting greater symptom severity.
Time frame: Pre-treatment, at week 15, and at the 7- and 16-month follow-ups
Montgomery-Åsberg Depression Rating Scale-Self-Rated (MADRS-S)
Measures symptom severity of depression. MADRS is a 9-item depressive symptoms scale where the symptoms are assessed on a 7-point likert scale from no symtoms to very high severity. The total score ranges from 0 to 54 with higher score indicating more severe problems.
Time frame: Pre-treatment, at week 15, and at the 7- and 16-month follow-ups
Work and Social Adjustment Scale (WSAS)
Measures impairment in functioning. Scores range from 0-40, with lower scores representing better functioning.
Time frame: Pre-treatment, at week 15, and at the 7- and 16-month follow-ups
Credibility/Expectancy Questionnaire (CEQ)
Measures treatment expectancy and rationale credibility. The CEQ is a 5-item measure of the treatment's credibility and the patients' expectations. The patients assess each domain on a 11-point likert scale (scored 0-10), with a total score ranging between 0-50 where higher score indicates higher credibility and higher expectations.
Time frame: Week 2
Working Alliance Inventory-Short Form Revised (WAI-SR)
Measures the therapeutic alliance in therapy. The WAI-SR is a 12-item measure of the patient's experience of their working alliance with the therapist. The patients assess each item on a 7-point likert scale (scored 0-6), with a total score ranging between 0-72 where higher score indicates higher better working alliance according to the patient.
Time frame: Week 2
Obsessive-Compulsive Inventory-Revised (OCI-R)
Self-rating scale that measures the severity and type of symptoms of OCD. The Obsessive-Compulsive Inventory-Revised (OCI-R) has 18 items. Each item is scored on a 5 point scale from 0 to 4. Total score ranges from 0 to 72, higher scores represent more severe OCD.
Time frame: Pre-treatment, at week 15, and at the 7- and 16-month follow-ups
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Raw data will be shared through a searchable database, Swedish national data service (SND), with restricted access. Only meta-data will be shared without restrictions. Researchers that want access to the raw data data will have to submit an additional application an ethical review board.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: The supporting information will become available for everybody on Open Science Framework (https://osf.io/w5bfp/) before inclusion of the first participant. We will not delete anything, potential changes will be transparently reported through time stamped documents. We plan to submit the raw data to SND after completion. We will never delete it.
Access criteria: Approved ethics application.
Data sharing details ↗ · snd.gu.se
Started Nov 2022 (actual). Primary completion is estimated for Aug 2024, 21 months after the start.
Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 21 months is below that.
Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obsessive-Compulsive Disorder →